Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness
Brief Summary: The objective of the study is to evaluate the effect of CPAP over the incidence of cardiovascular events and diagnosis of arterial hypertension in patients with sleep apnea.

The hypothesis of the study is the following: The existence of sleep disordered breathing in the general population is associated to an increased incidence of arterial hypertension and to an increased risk of suffering cardiovascular disease. CPAP corrects respiratory disorders during sleep. Treatment with CPAP in subjects with sleep disordered breathing without daytime sleepiness reduces the incidence of systemic arterial hypertension and cardiovascular complications.

The end points of the study are new diagnosis of arterial hypertension and new cardiovascular events.

All patients, after randomization, will be followed for three years.


Options:
A: Inclusion Criteria:

* Diagnosis of Alzheimer's disease based on the probability criteria of the Alzheimer's Disease and Related Disorders Association
* Rated 1 and 2 (mild to moderate level) on the Brazilian version of the Clinical Dementia Rating

Exclusion Criteria:

* Other causes of dementia
* Other severe medical or psychiatric disease
* Clinical indication of psychoactive drugs other than experimental drug
B: Inclusion Criteria:

* Epworth \<10
* Apnea-Hypopnea Index ≥20

Exclusion Criteria:

* Presence of any chronic disease
* Presence of cardiovascular disease
* Refusal to sign informed consent
* Drug addiction and/or alcoholism
C: Inclusion Criteria:

* Current diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS)
* Complaint of residual excessive sleepiness despite nasal continuous positive airway pressure (nCPAP) therapy being effective
* Current or prior diagnosis of major depressive disorder or dysthymic disorder
* Clinically stable with regard to depressed mood and has shown a treatment response to selective serotonin reuptake inhibitor (SSRI) therapy or serotonin and norepinephrine reuptake inhibitor (SNRI) therapy
* Patient has been on a stable monotherapy dose of an allowed SSRI or SNRI for at least 8 weeks at the time of screening
* Women of childbearing potential must use a medically accepted method of contraception.

Exclusion Criteria:

* Confirmed or suspected diagnosis of a currently active sleep disorder other than obstructive sleep apnea/hypopnea syndrome (OSAHS)
* Current episode of major depression that is considered to be treatment-resistant
* A primary diagnosis of: eating disorder, psychotic disorder, delirium, dementia, substance-related disorders, or moderate to severe hypochondriasis
* Patient has a history of bipolar disorder, psychotic depression, schizophrenia, schizoaffective disorder, any other psychotic disorder, or other clinically significant uncontrolled psychiatric condition.
* Patient has a history of homicidal ideation or significant aggression
* Patient has a diagnosis of severe antisocial or borderline personality disorder
* Has a history of significant suicidal ideation, or has current active suicidal ideation, or is considered at imminent risk of self harm.
* Patient has a history consistent with fibromyalgia or chronic fatigue syndrome
* A high consumption of caffeinated products, approximately equivalent to 5 or more cups of coffee per day
* Patient history of any clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction
* Has a past or present seizure disorder
* Patient has a history of alcohol, narcotic, or any other substance abuse or dependence (with the exception of nicotine)
* Psychotherapeutic intervention for the patient was initiated within 8 weeks of the screening visit.
* Patient has known human immunodeficiency virus (HIV)
* Patient has any clinically significant uncontrolled medical condition (including illnesses related to the cardiovascular, renal, or hepatic systems) or surgical condition (treated or untreated)
* Patient is a pregnant or lactating woman
* Patient has previously received armodafinil; or, patient has used modafinil or any investigational product within 28 days of the baseline visit.
D: Inclusion Criteria:

* Obstructive sleep apnea syndrome, successfully on CPAP therapy
* Residence at low altitude (\<800m)
* Obstructive apnea/hypopnea index \>20/h and a complaint of excessive daytime sleepiness before introduction of CPAP therapy.
* \>15 oxygen desaturations/h (\>3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP

Exclusion Criteria:

* Sleep disorders other than OSA.
* More than mild cardiovascular disease, unstable or recently diagnosed (within the last 6 months) cardiovascular disease such as arterial hypertension, coronary artery or cerebrovascular disease.
* Any lung disease, pulmonary hypertension.
* Chronic rhinitis.
* Treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline)
* Internal, neurologic or psychiatric disease that interfere with sleep quality.
* Previous intolerance to moderate or low altitude (\<2600m).
* Exposure to altitudes \>1500m for \>1 day within the last 4 weeks before the study

Answer: B